Die medikamentöse Therapie der Patientin mit Endometriose

Johannes Lermann; Janina Hackl; Stefanie Burghaus; Thomas Hildebrandt; Christine Fahlbusch; Stefan P. Renner; Matthias W. Beckmann

doi:10.1055/s-0042-122581

Frauenheilkunde up2date, Inhaltsverzeichnis

Frauenheilkunde up2date 2017; 11(01): 27-41
DOI: 10.1055/s-0042-122581

Allgemeine Gynäkologie

Georg Thieme Verlag KG Stuttgart · New York

Die medikamentöse Therapie der Patientin mit Endometriose

Johannes Lermann

,

Janina Hackl

,

Stefanie Burghaus

,

Thomas Hildebrandt

,

Christine Fahlbusch

,

Stefan P. Renner

,

Matthias W. Beckmann

Abstract

Alle Artikel dieser Rubrik

Symptome und Ausprägung einer Endometrioseerkrankung können vielschichtig sein. Therapeutisch steht die operative Resektion der Endometrioseläsionen im Vordergrund. Prä- und postoperativ ist eine medikamentöse Therapie zu diskutieren, in individuellen Fällen auch ohne vorherige histologische Sicherung. Zu beachten ist der Off-Label-Use bestimmter medikamentöser Therapien bei oftmals geringer Datenlage.

Volltext

Referenzen

Literatur
1 Knapp V. How old is endometriosis? Late 17th- and 18th century European descriptions of the disease. Fertil Steril 1999; 72: 10-14
2 Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991; 6: 544-549
3 Moen MH, Schei B. Epidemiology of endometriosis in a Norwegian county. Acta Obstet Gynecol Scand 1997; 76: 559-562
4 Viganò P, Parazzini F, Somigliana E. et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol 2004; 18: 177-200
5 Witz CA, Burns WN. Endometriosis and infertility: is there a cause and effect relationship?. Gynecol Obstet Invest 2002; 53 (Suppl. 01) 2-11
6 Simpson JL, Elias S, Malinak LR. et al. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980; 137: 327-331
7 Renner SP, Strick R, Oppelt P. et al. Evaluation of clinical parameters and estrogen receptor alpha gene polymorphisms for patients with endometriosis. Reproduction 2006; 131: 153-161
8 Sallam HN, Garcia-Velasco JA, Dias S. et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006; (01) CD004635
9 Walter AJ, Hentz JG, Magtibay PM. et al. Endometriosis: correlation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol 2001; 184: 1407-1411 discussion 1411–1413
10 Ulrich U, Nawroth F, Dorn C. Endometriose, Klinik, Diagnostik und Therapie. In: Ludwig M. Gynäkologische Endokrinologie und Reproduktionsmedizin. München: Hans Marseille; 2010: 219-227
11 Abbott J, Hawe J, Hunter D. et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82: 878-884
12 Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004; 16: 299-303
13 Ulrich U, Buchweitz O, Greb R. et al. National German guideline (S2k): Guideline for the diagnosis and treatment of endometriosis: long version – AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd 2014; 74: 1104-1118
14 Dunselman GA, Vermeulen N, Becker C. et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29: 400-412
15 Treloar SA, Bell TA, Nagle CM. et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 2010; 202: 534.e1-534.e6
16 Missmer SA, Hankinson SE, Spiegelman D. et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004; 104: 965-974
17 Hediger ML, Hartnett HJ, Louis GM. Association of endometriosis with body size and figure. Fertil Steril 2005; 84: 1366-1374
18 Parazzini F, La Vecchia C, Franceschi S. et al. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol 1989; 18: 108-112
19 Nouri K, Ott J, Krupitz B. et al. Family incidence of endometriosis in first-, second-, and third-degree relatives: case-control study. Reprod Biol Endocrinol 2010; 8: 85
20 Harada T, Momoeda M, Taketani Y. et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90: 1583-1588
21 Kirshon B, Poindexter 3rd AN. Contraception: a risk factor for endometriosis. Obstet Gynecol 1988; 71: 829-831
22 Strathy JH, Molgaard CA, Coulam CB. et al. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38: 667-672
23 Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306: 182-184
24 Allen C, Hopewell S, Prentice A. et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2009; (02) CD004753
25 Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005; (04) CD004753
26 Kennedy S, Bergqvist A, Chapron C. et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698-2704
27 Marjoribanks J, Proctor M, Farquhar C. et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; (01) CD001751
28 WHO. Scoping Document for WHO Guidelines for the pharmacological treatment of persisting pain in adults with medical illnesses. 2012 Im Internet: http://www.who.int/medicines/areas/quality_safety/guide_on_pain/en/ Stand: 20.01.2017
29 Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; (12) CD008475
30 Guzick DS, Huang LS, Broadman BA. et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95: 1568-1573
31 Zupi E, Marconi D, Sbracia M. et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82: 1303-1308
32 Davis L, Kennedy SS, Moore J. et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (03) CD001019
33 Vercellini P, Frontino G, De Giorgi O. et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560-563
34 Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001; (04) CD002120
35 Göretzlehner G. Menstrual bleeding – must that be? Extended use of oral hormonal contraception. Zentralbl Gynakol 2005; 127: 302-307
36 Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96
37 Mahutte NG, Arici A. Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am 2003; 30: 133-150
38 BfArM. Medizinprodukte. Venöse Thromboembolien und kombinierte hormonale Kontrazeptiva. 2016 Im Internet: http://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/KOK/_node.html/ Stand: 20.01.2017
39 Ludwig M. Kontrazeption – ab wann und wie lange?. Gynäkologe 2015; 48: 634-642
40 Vercellini P, Barbara G, Somigliana E. et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93: 2150-2161
41 Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000; (02) CD002122
42 Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012; (03) CD002122
43 Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72: 323-327
44 Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol 1987; 1: 363-371
45 Strowitzki T, Faustmann T, Gerlinger C. et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010; 151: 193-198
46 Petraglia F, Hornung D, Seitz C. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012; 285: 167-173
47 Strowitzki T, Marr J, Gerlinger C. et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25: 633-641
48 Kohler G, Faustmann TA, Gerlinger C. et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21-25
49 Andres Mde P, Lopes LA, Baracat EC. et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015; 292: 523-529
50 Vercellini P, Bracco B, Mosconi P. et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105: 734-743.e3
51 Klipping C, Duijkers I, Remmers A. et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 2012; 52: 1704-1713
52 Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005; 17: 359-365
53 Petta CA, Ferriani RA, Abrao MS. et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20: 1993-1998
54 Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012; 97: 616-622
55 Schweppe KW. Guidelines for the use of GnRH-analogues in the treatment of endometriosis. Zentralbl Gynakol 2005; 127: 308-313
56 Sagsveen M, Farmer JE, Prentice A. et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; (04) CD001297
57 Hornstein MD, Surrey ES, Weisberg GW. et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91: 16-24
58 Hornstein M, Gibbons W. Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists. 04.10.2016 Im Internet: https://www.uptodate.com Stand: 20.01.2017
59 Busacca M, Somigliana E, Bianchi S. et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III—IV: a randomized controlled trial. Hum Reprod 2001; 16: 2399-2402
60 Hornstein MD, Yuzpe AA, Burry KA. et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 1995; 63: 955-962
61 Vercellini P, Crosignani PG, Fadini R. et al. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 1999; 106: 672-677
62 Hornstein MD, Hemmings R, Yuzpe AA. et al. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68: 860-864
63 Strowitzki T, Thoene C, von Wolff M. Medikamentöse Behandlung der Endometriose. Journal für Fertilität und Reproduktion 2003; 3: 13-18
64 Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006; 12: 49-56
65 Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions – old answers?. Eur J Obstet Gynecol Reprod Biol 2005; 122: 144-150
66 Ferrero S, Gillott DJ, Venturini PL. et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol 2011; 9: 89
67 Nawathe A, Patwardhan S, Yates D. et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. Br J Obstet Gynaecol 2008; 115: 818-822
68 Rose PG, Alvarez B, Maclennan GT. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Am J Obstet Gynecol 2000; 183: 507-508
69 Altintas D, Kokcu A, Kandemir B. et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2010; 150: 84-87
70 Stratton P, Sinaii N, Segars J. et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008; 111: 88-96
71 Merviel P, Lourdel E, Sanguin S. et al. Interest of selective progesterone receptor modulators in endometriosis. Gynecol Obstet Fertil 2013; 41: 524-528
72 Kupker W, Felberbaum RE, Krapp M. et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002; 5: 12-16
73 Diamond MP, Carr B, Dmowski WP. et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014; 21: 363-371
74 Carr B, Dmowski WP, OʼBrien C. et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 2014; 21: 1341-1351
75 Hughes E, Brown J, Collins JJ. et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007; (03) CD000155
76 Deaton JL, Gibson M, Blackmer KM. et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54: 1083-1088
77 Tummon IS, Asher LJ, Martin JS. et al. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril 1997; 68: 8-12
78 Werbrouck E, Spiessens C, Meuleman C. et al. No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women with unexplained infertility after controlled ovarian hyperstimulation and intrauterine insemination. Fertil Steril 2006; 86: 566-571
79 Benaglia L, Somigliana E, Santi G. et al. IVF and endometriosis-related symptom progression: insights from a prospective study. Hum Reprod 2011; 26: 2368-2372
80 Benaglia L, Somigliana E, Vercellini P. et al. The impact of IVF procedures on endometriosis recurrence. Eur J Obstet Gynecol Reprod Biol 2010; 148: 49-52
81 Coccia ME, Rizzello F, Gianfranco S. Does controlled ovarian hyperstimulation in women with a history of endometriosis influence recurrence rate?. J Womens Health (Larchmt) 2010; 19: 2063-2069
82 Donnez J, Nisolle M, Gillet N. et al. Large ovarian endometriomas. Hum Reprod 1996; 11: 641-646
83 Muzii L, Marana R, Caruana P. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril 1996; 65: 1235-1237
84 Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4: 312-322
85 Bragheto AM, Caserta N, Bahamondes L. et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76: 195-199
86 Fedele L, Bianchi S, Raffaelli R. et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68: 426-429
87 Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999; 60: 173-175
88 Kitawaki J. Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 2006; 20: 493-502
89 Sheng J, Zhang WY, Zhang JP. et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79: 189-193
90 Renner SP, Rix S, Boosz A. et al. Preoperative pain and recurrence risk in patients with peritoneal endometriosis. Gynecol Endocrinol 2010; 26: 230-235
91 Renner SP, Lermann J, Hackl J. et al. Chronische Erkrankung. Endometriose. Geburtshilfe Frauenheilkd 2012; 72: 914-919
92 Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004; (03) CD003678
93 Abou-Setta AM, Houston B, Al-Inany HG. et al. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2013; (01) CD005072
94 Vercellini P, Somigliana E, Viganò P. et al. Post-operative endometriosis recurrence: a plea for prevention based on pathogenetic, epidemiological and clinical evidence. Reprod Biomed Online 2010; 21: 259-265
95 Seracchioli R, Mabrouk M, Manuzzi L. et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod 2009; 24: 2729-2735
96 Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37-43